Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764

    CAS  Article  Google Scholar 

  2. 2

    Kantoff PW et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506–2513

    CAS  Article  Google Scholar 

  3. 3

    Berry W et al. (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443

    CAS  Article  Google Scholar 

  4. 4

    Abratt RP et al. (2004) Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15: 1613–1621

    CAS  Article  Google Scholar 

  5. 5

    Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    CAS  Article  Google Scholar 

  6. 6

    National Institute of Health (NIH) (Online 17 December 2004) Clinical trials. (Accessed 6 November 2004)

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gerrit Stoter.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sleijfer, S., Stoter, G. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Clin Oncol 2, 70–71 (2005). https://doi.org/10.1038/ncponc0076

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing